MoH orders on the program of access for study subjects (patients) to the investigational medicinal product after completion of the clinical trial

MoH order of 06 August 2026 No. 1086

10.08.2026 270

MoH order of 06.08.2026 No. 1086 approves a program for patient access to an investigational medicinal product after completion of a clinical trial. The appendix defines the conditions for providing the drug for the prevention of bleeding to patients with hemophilia who previously participated in studies. generated automatically

MoH order of 29 May 2026 No. 719

03.06.2026 424

MoH of Ukraine order of 29 May 2026 No. 719 approves amendments to the program of patient access to the investigational medicinal product after completion of the clinical trial. The document updates the expected number of packages of the product, the list of healthcare facilities and doctors involved in the program, and the projected number of patients. generated automatically

MoH order of 16 April 2026 No. 511

23.04.2026 760

Order of the Ministry of Health of Ukraine of 16.04.2026 No. 511 approves a program of patient access to the investigational medicinal product after completion of the clinical trial. The annex defines the conditions, terms and volumes of supply of the medicinal product, the applicant and the healthcare facilities involved in the program. compiled automatically

MoH order of 20 March 2026 No. 368

10.04.2026 706

MoH order of 20.03.2026 No.368 approves amendments to the program of patient access to the investigational medicinal product after completion of the clinical trial. The document updates the expected number of packages of the medicine, the list of healthcare institutions and doctors involved in the program, and the projected number of patients. compiled automatically

MoH order of 02 December 2025 No. 1831

08.12.2025 749

The program for patient access to the investigational medicinal product after completion of the clinical trial has been approved. The document defines the conditions, duration, quantity of the product, the healthcare facility involved and the patient population. generated automatically

MoH order of 14 October 2025 No. 1724

20.11.2025 1010

MoH of Ukraine order of 14.10.2025 No. 1724 on refusal to approve the program of patient access to the investigational medicinal product after completion of the clinical trial. The document contains the decision on refusal and an annex with details of the program. compiled automatically

MoH order of 11 October 2025 No. 1551

15.10.2025 1151

MoH order of 11 October 2025 No. 1551 on refusal to approve the program of access of trial subjects (patients) to the investigational medicinal product after completion of a clinical trial. The document contains the refusal decision and an annex with details of the relevant program. generated automatically

MoH order of 18 September 2025 No. 1449

19.09.2025 1086

MoH order of 18.09.2025 No. 1449 amends the annex to the MoH order of 09.04.2024 No. 596, restating line 9 in a new wording. The document updates the list of healthcare institutions and doctors involved in conducting the program of patient access to the investigational medicinal product after completion of the clinical trial. compiled automatically

MoH order of 28 August 2025 No. 1348

29.08.2025 1584

A program of patient access to investigational medicinal products after completion of a clinical trial has been approved. The document defines the conditions, terms, and the list of healthcare facilities and doctors for providing treatment to patients with non-small cell lung cancer. compiled automatically

MoH order of 11 July 2025 No. 1103

14.07.2025 1399

MoH of Ukraine order No. 1103 of 11.07.2025 on refusal to approve a program of patient access to an investigational medicinal product after completion of a clinical trial. The annex contains detailed parameters of this program: the product, applicant, duration, number of patients, and healthcare facilities. generated automatically